Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia

Ascher-Svanum, Haya; Stensland, Michael; Zhongyun Zhao; Kinon, Bruce J.
January 2005
BMC Psychiatry;2005, Vol. 5, p3
Academic Journal
Background: Previous research indicated that women are more vulnerable than men to adverse psychological consequences of weight gain. Other research has suggested that weight gain experienced during antipsychotic therapy may also psychologically impact women more negatively. This study assessed the impact of acute treatment-emergent weight gain on clinical and functional outcomes of patients with schizophrenia by patient gender and antipsychotic treatment (olanzapine or haloperidol). Methods: Data were drawn from the acute phase (first 6-weeks) of a double-blind randomized clinical trial of olanzapine versus haloperidol in the treatment of 1296 men and 700 women with schizophrenia-spectrum disorders. The associations between weight change and change in core schizophrenia symptoms, depressive symptoms, and functional status were examined post-hoc for men and women and for each medication group. Core schizophrenia symptoms (positive and negative) were measured with the Brief Psychiatric Rating Scale (BPRS), depressive symptoms with the BPRS Anxiety/Depression Scale and the Montgomery-Asberg Depression Rating Scale, and functional status with the mental and physical component scores on the Medical Outcome Survey-Short Form 36. Statistical analysis included methods that controlled for treatment duration. Results: Weight gain during 6-week treatment with olanzapine and haloperidol was significantly associated with improvements in core schizophrenia symptoms, depressive symptoms, mental functioning, and physical functioning for men and women alike. The conditional probability of clinical response (20% reduction in core schizophrenia symptom), given a clinically significant weight gain (at least 7% of baseline weight), showed that about half of the patients who lost weight responded to treatment, whereas three-quarters of the patients who had a clinically significant weight gain responded to treatment. The positive associations between therapeutic response and weight gain were similar for the olanzapine and haloperidol treatment groups. Improved outcomes were, however, more pronounced for the olanzapine-treated patients, and more olanzapine-treated patients gained weight. Conclusions: The findings of significant relationships between treatment-emergent weight gain and improvements in clinical and functional status at 6-weeks suggest that patients who have greater treatment-emergent weight gain are more likely to benefit from treatment with olanzapine or haloperidol regardless of gender.


Related Articles

  • Metformin and Berberine Prevent Olanzapine-Induced Weight Gain in Rats. Hu, Yueshan; Young, Alan J.; Ehli, Erik A.; Nowotny, Dustin; Davies, Paige S.; Droke, Elizabeth A.; Soundy, Timothy J.; Davies, Gareth E. // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Olanzapine is a first line medication for the treatment of schizophrenia, but it is also one of the atypical antipsychotics carrying the highest risk of weight gain. Metformin was reported to produce significant attenuation of antipsychotic-induced weight gain in patients, while the study of...

  • Preventing Olanzapine-Induced Weight Gain Using Betahistine: A Study in a Rat Model with Chronic Olanzapine Treatment. Lian, Jiamei; Huang, Xu-Feng; Pai, Nagesh; Deng, Chao // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Olanzapine is the one of first line antipsychotic drug for schizophrenia and other serious mental illness. However, it is associated with troublesome metabolic side-effects, particularly body weight gain and obesity. The antagonistic affinity to histamine H1 receptors (H1R) of antipsychotic...

  • Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis. Bak, Maarten; Fransen, Annemarie; Janssen, Jouke; van Os, Jim; Drukker, Marjan // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Introduction: Antipsychotics (AP) induce weight gain. However, reviews and meta-analyses generally are restricted to second generation antipsychotics (SGA) and do not stratify for duration of AP use. It is hypothesised that patients gain more weight if duration of AP use is longer. Method: A...

  • Olanzapine-Induced Hyperphagia and Weight Gain Associate with Orexigenic Hypothalamic Neuropeptide Signaling without Concomitant AMPK Phosphorylation. Fernø, Johan; Varela, Luis; Skrede, Silje; Vázquez, María Jesús; Nogueiras, Rubén; Diéguez, Carlos; Vidal-Puig, Antonio; Steen, Vidar M.; López, Miguel // PLoS ONE;2011, Vol. 6 Issue 6, p1 

    The success of antipsychotic drug treatment in patients with schizophrenia is limited by the propensity of these drugs to induce hyperphagia, weight gain and other metabolic disturbances, particularly evident for olanzapine and clozapine. However, the molecular mechanisms involved in...

  • New class of antipsychotic drugs for schizophrenia. Breier, Alan // Cortlandt Forum;07/25/97, Vol. 10 Issue 7, p23 

    Describes antipsychotic drugs for the treatment of schizophrenia in the United States. Clozapine; Risperidone; Olanzapine; Sertindole; Comparison to haloperidol-like drugs.

  • Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. Johnsen, Erik; A.^Kroken, Rune; Wentzel-Larsen, Tore; A.^Jørgensen, Hugo // BMC Psychiatry;2010, Vol. 10, p26 

    Background: No clear recommendations exist regarding which antipsychotic drug should be prescribed first for a patient suffering from psychosis. The primary aims of this naturalistic study were to assess the head-to-head effectiveness of first-line second-generation antipsychotics with regards...

  • Increased mortality among elderly patients with dementia using atypical antipsychotics. Singh, Sonal; Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;8/2/2005, Vol. 173 Issue 3, p252 

    Discusses research being done on the use of atypical anti-psychotic drugs in the treatment of behavioral and psychological symptoms of dementia. Reference to a study by P. E. Lee, S. S. Freedman et al, published in the 2004 issue of the "British Medical Journal"; Incidence of death among...

  • Correlation of qEEG with PET in Schizophrenia. Alper, Kenneth; Günther, Wilfred; Prichep, Leslie S.; John, E. Roy; Brodie, Jonathan // Neuropsychobiology;1998, Vol. 38 Issue 1, p50 

    PET relative metabolism was correlated with quantitative EEG in 9 schizophrenic patients. The PET metabolic regions of interest were the frontal lobes, thalamus and basal ganglia, and right and left temporal lobes. Significant positive correlations were seen for the frontal lobes and delta EEG...

  • Haloperidol.  // AHFS Consumer Medication Information;May2020, p1 

    Haloperidol is used to treat psychotic disorders (conditions that cause difficulty telling the difference between things or ideas that are real and things or ideas that are not real). Haloperidol is also used to control motor tics (uncontrollable need to repeat certain body movements) and verbal...

  • antipsychotic.  // Taber's Cyclopedic Medical Dictionary;2005, p140 

    A definition of the medical term "antipsychotic" is presented. Antipsychotic refers to the prevention or treatment of psychosis or a medication used to treat psychosis. The term originated from the Greek words "anti" which means against, and "psyche" which means mind or soul. The definition is...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics